 Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved advantageous for some biotechs that disclosed plans to work on therapies or vaccines for countering the viral attack. The FDA approved Esperion Therapeutics Incs NASDAQ: ESPR LDL-cholesterol lowering combo therapy and Biohaven Pharmaceutical Holding Co Ltds NYSE: BHVN migraine drug . The following are key catalysts that could move biotech stocks in the unfolding week. Conferences Cowen 40th Annual Healthcare Conference: March 2-4 in Boston, Massachusetts Related Link: Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug Earnings Monday Albireo Pharma Inc NASDAQ: ALBO before the market open Amicus Therapeutics, Inc. NASDAQ: FOLD before the market open Intra-Cellular Therapies Inc NASDAQ: ITCI before the market open Seres Therapeutics Inc NASDAQ: MCRB before the market open Urogen Pharma Ltd NASDAQ: URGN ... 